In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

ZymoGenetics licenses clotting factor to Novo Nordisk

Executive Summary

With hopes to free up resources for other projects while still benefiting from future economic returns, ZymoGenetics (protein therapeutics) has licensed to Novo Nordisk exclusive worldwide rights to its recombinant Factor XIII (rFactor XIII) and all related intellectual property.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Concluded
Deal Type
  • Alliance
    • Includes Contract
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register